Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 11/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | PDE1A | P54750 | 2/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291504 | 0.89 | CCR1 (0.38) | QPCTCTNNB1WNT3AQPCTLMEN1 | |
| SCHEMBL4306355 | 0.82 | CCR1 (0.39) | QPCTQPCTLMEN1ALDH1A1HPGD | |
| SCHEMBL4298512 | 0.81 | QPCT (0.36) | QPCTPDE2APDE1APDE1BPDE1C | |
| SCHEMBL4296200 | 0.81 | CCR2 (0.38) | QPCT | |
| SCHEMBL4296935 | 0.79 | QPCT (0.37) | QPCTQPCTLMEN1ALDH1A1HPGD | |
| SCHEMBL4300278 | 0.79 | MEN1 (0.37) | QPCTQPCTLMEN1ALDH1A1HPGD | |
| SCHEMBL4300392 | 0.78 | CCR1 (0.38) | QPCT | |
| SCHEMBL4300404 | 0.78 | CCR1 (0.43) | QPCTMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL4299447 | 0.78 | MEN1 (0.37) | QPCTHTTMEN1ALDH1A1HPGD | |
| SCHEMBL4298461 | 0.76 | CCR1 (0.39) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | claimed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | claimed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | claimed |
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | disclosed |
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | QPCT 4/4885PDE2A 715/4885PDE1A 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.